Sekar Kathiresan - Jun 28, 2024 Form 4 Insider Report for Verve Therapeutics, Inc. (VERV)

Role
Chief Executive Officer, Director
Signature
/s/ Andrew Ashe, as Attorney-in-Fact for Sekar Kathiresan
Stock symbol
VERV
Transactions as of
Jun 28, 2024
Transactions value $
$86,100
Form type
4
Date filed
7/2/2024, 07:30 AM
Previous filing
Jun 5, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VERV Common Stock Options Exercise $86.1K +30K +9.34% $2.87 351K Jun 28, 2024 Direct F1
holding VERV Common Stock 241K Jun 28, 2024 Kathiresan Family 2021 Irrevocable Trust
holding VERV Common Stock 81K Jun 28, 2024 Sekar Kathiresan 2021 Irrevocable Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VERV Stock Option (right to buy) Options Exercise $0 -30K -12.23% $0.00 215K Jun 28, 2024 Common Stock 30K $2.87 Direct F2
holding VERV Stock Option (right to buy) 160K Jun 28, 2024 Common Stock 160K $2.87 Sekar Kathiresan 2022 Annuity Trust F3
holding VERV Stock Option (right to buy) 200K Jun 28, 2024 Common Stock 200K $2.87 Sekar Kathiresan 2023 Annuity Trust F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Includes 4,918 shares of the Company's common stock acquired under the Verve Therapeutics, Inc. Amended and Restated 2021 Employee Stock Purchase Plan.
F2 The remaining shares underlying this option, which was granted on September 16, 2020, vest in equal monthly installments until September 16, 2024.
F3 The shares underlying the option were fully vested when transferred.